You are here: Industry Insights > Market News > AstraZeneca expects EUA in US for COVID-19 vaccine in April

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

AstraZeneca expects EUA in US for COVID-19 vaccine in April

expresspharmaFebruary 25, 2021

Tag: AstraZeneca , COVID-19 Vaccine , EUA

Favorites

AstraZeneca expects its COVID-19 vaccine could receive US Emergency Use Authorisation (EUA) at the beginning of April and could immediately deliver 30 million doses of the shot there, a top executive said at a hearing in the US House of Representatives.

Ruud Dobber, Executive VP at AstraZeneca, said that the drugmaker expects to be able to deliver 50 million doses of the vaccine by the end of April.

Previous:Cabinet nod for pharma PLI Scheme

Next:Granules India gets USFDA approval for OTC Acetaminophen, Aspirin and Caffeine Tablets

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Biotech NewswireMay 09, 2024

AstraZeneca expects EUA in US for COVID-19 vaccine in April | Pharmasources.com

Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore

ACN NewswireMay 09, 2024

The Company will continue to store cord blood units for these clients until the maturity of their service agreements when their children turn 21, without charge.

AstraZeneca expects EUA in US for COVID-19 vaccine in April

Related News

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore

You may like